Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults

Juandy Jo; Astia Sanjaya; Reinhard Pinontoan; Maroloan Aruan; Rury Mega Wahyuni; Venansi Viktaria

doi:10.7774/cevr.2022.11.1.116

Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults

Clin Exp Vaccine Res. 2022 Jan;11(1):116-120. doi: 10.7774/cevr.2022.11.1.116. Epub 2022 Jan 31.

Authors

Juandy Jo^{1

2}, Astia Sanjaya¹, Reinhard Pinontoan¹, Maroloan Aruan³, Rury Mega Wahyuni², Venansi Viktaria²

Affiliations

¹ Department of Biology, Universitas Pelita Harapan, Tangerang, Indonesia.
² Mochtar Riady Institute for Nanotechnology, Tangerang, Indonesia.
³ Department of Pharmacy, Universitas Pelita Harapan, Tangerang, Indonesia.

Abstract

The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.

Keywords: Anti-SARS-CoV-2 RBD antibody; COVID-19; CoronaVac vaccine.